Chr Hansen and Lonza appoint new CEO for BacThera


Chr Hansen and Lonza joint venture company focuses on live-biotherapeutics has appointed Lukas Schüpbach as CEO

The Board of Directors of BacThera has appointed Lukas Schüpbach as CEO as of 1 February 2020. Lukas Schüpbach comes from a position as global head of Strategy and Operations at Emavant Solutions, was co-founder of Innojection and has previously held senior leadership positions at Syngenta and Novartis.

Schüpbach holds a master’s degree in Business from the University of Basel and a master’s degree in Economics from the HEC in Lausanne.

CEO of Chr. Hansen and Chairman of the Board at BacThera, Mauricio Graber said: “BacThera gets a CEO with a rounded profile, from an entrepreneurial mindset to building and aligning cross functional teams in large organisations. I am convinced his pharma experience, and extensive network, will be very valuable for BacThera’s growth plans and the company’s ambition to be a pioneer in the emerging live-biotherapeutic market.”

Commenting on his appointment, Schüpbach said: “The nature of the company allows me to combine my experience from the life-sciences industry and the biotech start up scene, contributing to ultimately realise BacThera’s strong purpose of bringing life-changing treatments to patients.”

BacThera’s interim CEO, Christian Bigum, continues as acting CEO until Lukas Schüpbach takes up his new position in February.

Sign up for your free email newsletter

Bigum said: “Lukas and I have already planned a solid transition that will ensure full alignment on BacThera’s strategy and priorities while maintaining the strong business momentum we have right now. I am pleased to handover the torch to Lukas – he is not only a strong business builder and charismatic leader, but also sincerely inspired by BacThera’s purpose of shaping the future of medicine.”